148 related articles for article (PubMed ID: 22168970)
1. Effect of valproic acid on the outcome of glioblastoma multiforme.
Tsai HC; Wei KC; Tsai CN; Huang YC; Chen PY; Chen SM; Lu YJ; Lee ST
Br J Neurosurg; 2012 Jun; 26(3):347-54. PubMed ID: 22168970
[TBL] [Abstract][Full Text] [Related]
2. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme.
Guthrie GD; Eljamel S
J Neurosurg; 2013 Apr; 118(4):859-65. PubMed ID: 23176328
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
4. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
5. Influence of valproic acid on outcome of high-grade gliomas in children.
Masoudi A; Elopre M; Amini E; Nagel ME; Ater JL; Gopalakrishnan V; Wolff JE
Anticancer Res; 2008; 28(4C):2437-42. PubMed ID: 18751431
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Papi A; Ferreri AM; Rocchi P; Guerra F; Orlandi M
Anticancer Res; 2010 Feb; 30(2):535-40. PubMed ID: 20332466
[TBL] [Abstract][Full Text] [Related]
7. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Hosein AN; Lim YC; Day B; Stringer B; Rose S; Head R; Cosgrove L; Sminia P; Fay M; Martin JH
J Neurooncol; 2015 Apr; 122(2):263-71. PubMed ID: 25648357
[TBL] [Abstract][Full Text] [Related]
8. The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis.
Lu VM; Texakalidis P; McDonald KL; Mekary RA; Smith TR
Clin Neurol Neurosurg; 2018 Nov; 174():149-155. PubMed ID: 30243186
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review.
Yuan Y; Xiang W; Qing M; Yanhui L; Jiewen L; Yunhe M
Seizure; 2014 Nov; 23(10):830-5. PubMed ID: 25066904
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
11. Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Ochiai S; Nomoto Y; Yamashita Y; Watanabe Y; Toyomasu Y; Kawamura T; Takada A; Ii N; Kobayashi S; Sakuma H
Asian Pac J Cancer Prev; 2016; 17(2):463-6. PubMed ID: 26925628
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
[TBL] [Abstract][Full Text] [Related]
13. Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock.
Gonzales ER; Chen H; Munuve RM; Mehrani T; Nadel A; Koustova E
J Trauma; 2008 Sep; 65(3):554-65. PubMed ID: 18784568
[TBL] [Abstract][Full Text] [Related]
14. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
Wheeler CJ; Das A; Liu G; Yu JS; Black KL
Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
16. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
[TBL] [Abstract][Full Text] [Related]
18. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
20. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
